Table_2_Shared sex hormone metabolism-related gene prognostic index between breast and endometrial cancers.csv

AimsAs sex hormone-dependent tumors, it remains to be clarified whether there is a common genetic signature and its value between breast and endometrial cancers. The aim of this study was to establish the shared sex hormone metabolism-related gene prognostic index (SHMRGPI) between breast and endometrial cancers and to analyze its potential role in the therapeutic and prognostic assessment of endometrial cancers.MethodsUsing transcriptome data from TCGA, tumor-associated gene modules were identified by weighted gene co-expression network analysis, and the intersection of module genes with female sex hormone synthesis and metabolism genes was defined as sex hormone metabolism-related gene. SHMRGPI was established by the least absolute shrinkage and selection operator and Cox regression. Its prognostic value of patients with endometrial cancer was validated, and a nomogram was constructed. We further investigated the relationship between SHMRGPI groups and clinicopathological features, immune infiltration, tumor mutation burden, and drug sensitivity.ResultsA total of 8 sex hormone metabolism-related gene were identified as key genes for the construction of prognostic models. Based on SHMRGPI, endometrial cancer patients were divided into high and low SHMRGPI groups. Patients in the low SHMRGPI group had longer overall survival (OS) compared with the high group (P< 0.05). Furthermore, we revealed significant differences between SHMRGPI groups as regards tumor immune cell infiltration, somatic mutation, microsatellite instability and drug sensitivity. Patients with low SHMRGPI may be the beneficiaries of immunotherapy and targeted therapy.ConclusionsThe SHMRGPI established in this study has prognostic power and may be used to screen patients with endometrial cancer who may benefit from immunotherapy or targeted therapy.

本研究的宗旨在于阐明作为性激素依赖性肿瘤的乳腺癌与子宫内膜癌之间是否存在共同的遗传标志及其价值。本研究旨在建立乳腺癌与子宫内膜癌间共享的性激素代谢相关基因预后指数（SHMRGPI），并分析其在子宫内膜癌治疗和预后评估中的潜在作用。研究方法：利用TCGA转录组数据，通过加权基因共表达网络分析识别肿瘤相关基因模块，并将模块基因与女性性激素合成和代谢基因的交集定义为性激素代谢相关基因。通过最小绝对收缩和选择算子以及Cox回归建立SHMRGPI。验证了其在子宫内膜癌患者预后中的价值，并构建了预后图。进一步研究了SHMRGPI组与临床病理特征、免疫浸润、肿瘤突变负荷和药物敏感性的关系。结果：共确定了8个性激素代谢相关基因作为构建预后模型的关键基因。基于SHMRGPI，子宫内膜癌患者被分为高SHMRGPI组和低SHMRGPI组。与高SHMRGPI组相比，低SHMRGPI组的患者总生存期（OS）更长（P<0.05）。此外，我们还揭示了SHMRGPI组在肿瘤免疫细胞浸润、体细胞突变、微卫星不稳定性以及药物敏感性方面的显著差异。低SHMRGPI组的患者可能从免疫治疗和靶向治疗中获益。结论：本研究建立的SHMRGPI具有预后价值，可用于筛选可能从免疫治疗或靶向治疗中获益的子宫内膜癌患者。